Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Global, Multi-Arm Study to Evaluate the Efficacy and Safety of Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers (BELLA)

NCT06906341 is registered in ClinicalTrials.gov with Corcept Therapeutics as lead sponsor.

NCT NCT06906341
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06906341 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Global, Multi-Arm Study to Evaluate the Efficacy and Safety of Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers (BELLA)
Lead sponsor
Corcept Therapeutics
Phase
Phase 2
Overall status
Recruiting
Start date
April 11, 2025
Completion date
December 31, 2026
Enrollment
270 (estimated)
Sites
49

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial cancer, fallopian tube cancer, ovarian cancer, peritoneal neoplasms